Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B. Daly, Mary A. Dwyer, Tuya Pal et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B. Daly, Susan Darlow, Wendy Kohlmann et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 507
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian CancerTimothy R. Rebbeck, Saundra S. Buys, Nandita Mitra et al.|JAMA|2015Cited by 507